A HIGHLY VALIDATED RP-HPLC METHOD DEVELOPMENT FOR THE SIMULTANEOUS ESTIMATION OF DAPAGLIFLOZIN AND SAXAGLIPTIN IN TABLET DOSAGE FORMS
Abstract
A simple, accurate, precise method was developed for the simultaneous estimation of Dapagliflozin and Saxagliptin in Tablet dosage form. Chromatogram was run through Standard BDS C8 column (50 × 4.6 mm, 5m) The Mobile phase containing Potassium dihydrogen phosphate: Acetonitrile in the ratio 55:45, pH was adjusted to 3.8 with dilute orthophosphoric acid. The solution was pumped through the column at a flow rate of 1 ml/min. The column temperature was maintained at 30°C. Optimized wavelength selected was 210 nm. Retention time of Dapagliflozin and Saxagliptin were found to be 2.266 min and 2.805 min. % RSD of the Dapagliflozin and Saxagliptin were found to be 0.5 and 0.5 respectively. % Recovery was obtained as 98.98% and 98.72% for Dapagliflozin and Saxagliptin respectively. LOD, LOQ values obtained from regression equations of Dapagliflozin and Saxagliptin were 0.20, 0.60 and 0.26, 0.79 respectively. Regression equation of Dapagliflozin is y = 37377x + 89244, and y =12254x + 3122 of Saxagliptin. The retention times were decreased so that the run time also decreased. So the method developed was simple and economical that can be applied successfully for simultaneous estimation of both Dapagliflozin and Saxagliptin in bulk and combined tablet formulation.
Keywords:
Dapagliflozin, Saxagliptin, RP-HPLC, Validation, Simultaneous estimationDOI
https://doi.org/10.25004/IJPSDR.2018.100503References
2. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with Dapagliflozin in type 2 diabetes. Diabetes Care. 2009; 32:650–57.
3. Kalra S, Ghosh S, Aamir AH, Ahmed MT, Amin MF, Bajaj S, et al. Safe and pragmatic use of sodium–glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement. Indian J Endocrinol Metab. 2017; 21(1): 210-230.
4. Mikhail N. Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes. World J Diabetes 2014; 5(6): 854–859.
5. Hinnen D. Glucuretic effects and renal safety of Dapagliflozin in patients with type 2 diabetes. Ther Adv Endocrinol Metab. 2015; 6(3): 92–102.
6. Kilov G, Leow S, Thomas M. Clinical SGLT2 inhibition with Dapagliflozin A novel approach for the management of type 2 diabetes. AFP 2013; 42(10):706-710.
7. Chao EC. Do SGLT-2 Inhibitors: A New Mechanism for Glycemic Control. Clin Diabetes 2014; 32(1): 4–11.
8. Vivian EM. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents. Drugs Context. 2014; 3: 212264.
9. Bays H. Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus. Diabetes Ther. 2013; 4(2): 195–220.
10. Pathak R, Bridgeman MB. Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in the Management of Diabetes. P T. 2010; 35(9): 509–513.
11. Crepaldi G, Carruba M, Comaschi M, Del Prato S, Frajese G, Paolisso G. Dipeptidyl peptidase 4 (DPP-4) inhibitors and their role in Type 2 diabetes management. J Endocrinol Invest. 2007; 30(7):610-4.
12. ICH Harmonised Tripartite Guideline, validation of analytical procedures: Text methodology, Q2 (R1) (2005). International Conference on Harmonization, Geneva, pp: 1-13.
13. Debata J, Kumar S, Jha SK, Khan A. A New RP-HPLC Method Development and Validation of Dapagliflozin in Bulk and Tablet Dosage Form. International Journal of Drug Development and Research. 2017; 9:48-51.
14. Yunoos M, Sankar G. A validated stability indicating high-performance liquid chromatographic method for simultaneous determination of Metformin HCl and Dapagliflozin in bulk drug and tablet dosage form. Asian J Pharm Clin Res. 2015; 8(3): 320-326.
15. Prasad PBN, Satyanaryana K, Krishnamohan G. Development and Validation of a Method for Simultaneous Determination of Metformin and Saxagliptin in a Formulation by RP-HPLC. American Journal of Analytical Chemistry. 2015; (6): 841-850.
16. Patel PD, Pandya SS. Validated RP – HPLC Method for Simultaneous Estimation of Dapagliflozin and Saxagliptin Hydrochloride in Tablet Dosage Form. International Journal for Pharmaceutical Research Scholars. 2018; 7 (1): 9-15.
17. Singh N, Bansal P, Maithani M, Chauhan Y. Development and validation of a stability indicating RP-HPLC method for simultaneous determination of Dapagliflozin and Saxagliptin in fixed-dose combination. New J. Chem. 2018; 42: 2459-2466.
18. Deepan T, Dhanaraju MD. Stability indicating HPLC method for the simultaneous determination of Dapagliflozin and Saxagliptin in bulk and tablet dosage form. Curr. Issues Pharm. Med. Sci. 2018; 31(1):39-43.
Published
Abstract Display: 1671 
PDF Downloads: 0 
